A 5-year-old child is admitted to the pediatric unit with a diagnosis of community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) skin and soft tissue infection. The child has completed 48 hours of intravenous vancomycin therapy. Which nursing intervention is most appropriate at this time?

Continuing vancomycin therapy with close monitoring is essential for CA-MRSA treatment success and patient safety. Discontinuing precautions, discharge planning, or switching to oral antibiotics prematurely can lead to treatment failure or resistance.

Understanding the Clinical Scenario

A 5-year-old child with a confirmed community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) skin and soft tissue infection has been receiving intravenous vancomycin for 48 hours. At this juncture, the most appropriate nursing intervention is to continue the current antibiotic therapy and monitor for clinical improvement and adverse effects.

Pathophysiology and Pharmacologic Rationale

CA-MRSA infections are driven by S. aureus strains that have acquired the mecA gene, rendering them resistant to beta-lactam antibiotics. Vancomycin, a glycopeptide, remains a cornerstone of treatment for serious MRSA infections. Its mechanism involves binding to the D-alanyl-D-alanine terminus of peptidoglycan precursors, inhibiting cell wall synthesis. The effectiveness of vancomycin is best predicted by the pharmacokinetic/pharmacodynamic (PK/PD) index of the 24-hour area under the concentration-time curve to minimum inhibitory concentration ratio (AUC/MIC). A target AUC/MIC ratio of ≥400 is associated with clinical efficacy, a goal that requires consistent dosing and time to achieve steady-state concentrations ^[1].

A 48-hour window is insufficient to confirm full clinical resolution of a deep-seated or severe CA-MRSA infection. While early signs of improvement may be present, the bacterial burden is not yet eradicated. Premature discontinuation or a switch to oral therapy without clear evidence of clinical stability risks treatment failure and the development of resistance. The emergence of vancomycin-intermediate S. aureus (VISA) and vancomycin-resistant S. aureus (VRSA) is a grave global concern, driven in part by suboptimal vancomycin exposure ^[4]. The adaptive mechanism for VISA involves cell wall thickening and altered autolytic activity, which can develop under prolonged or inadequate dosing pressure ^[4]. Therefore, maintaining a consistent, therapeutic regimen is a critical stewardship principle.

Analysis of Incorrect Options

Discontinuing contact precautions after only 48 hours of antibiotic therapy is premature and contradicts infection control standards. CA-MRSA colonization and active infection require transmission-based precautions until the infection is resolved and drainage is contained, regardless of antibiotic duration. The molecular epidemiology of CA-MRSA in pediatric populations shows diverse and virulent clones circulating in the community, underscoring the ongoing transmission risk .

Preparing for discharge planning under the assumption that the infection "should be resolving" is a clinical judgment error. While a case report of a complicated CA-MRSA hepatic abscess demonstrated successful treatment with a prolonged, culture-guided course (14 days of intravenous ciprofloxacin followed by oral therapy), this highlights that treatment duration is dictated by clinical response and infection severity, not a fixed 48-hour timeline . A skin and soft tissue infection requires objective evidence of improvement, such as decreased erythema, induration, and purulence, before discharge is considered.

Switching to oral antibiotics immediately to avoid vancomycin-related complications is not supported by evidence at this 48-hour mark. While nephrotoxicity is a known adverse effect of vancomycin, current research focuses on optimizing dosing strategies—such as comparing continuous versus intermittent infusion—to enhance AUC/MIC target attainment while monitoring renal safety ^[1]. The priority is to first ensure therapeutic efficacy. The decision to de-escalate or transition to an oral agent with CA-MRSA activity is based on culture and sensitivity results, clinical stability, and the ability of the child to tolerate oral intake, not solely on the fear of adverse effects.

Clinical Nursing Synthesis

The nurse's role at this 48-hour point is vigilant monitoring. This includes assessing the infection site for signs of improvement, monitoring vital signs for ongoing systemic response, and evaluating for adverse drug reactions. Crucially, vancomycin trough levels (for intermittent dosing) or steady-state concentrations (for continuous infusion) are monitored to ensure the AUC/MIC target is met without reaching toxic levels, a practice aligned with the goal of individualized dosing protocols to enhance first-dose attainment of steady-state concentrations ^[1]. The nurse must also maintain strict infection control practices to prevent transmission, given that pediatric CA-MRSA isolates in community settings carry significant molecular diversity and pathogenic potential . The therapy should continue uninterrupted, with the treatment team evaluating objective clinical data to guide the next steps in care.